(LXRX) Lexicon - Performance -62.5% in 12m
Compare LXRX with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-70.65%
#98 in Group
Rel. Strength
7.89%
#7329 in Universe
Total Return 12m
-62.51%
#126 in Group
Total Return 5y
-67.09%
#71 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -0.14
46th Percentile in Group
FCF Yield -
(?) Percentile in Group
12m Total Return: LXRX (-62.5%) vs XBI (-14.9%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
7.21% | 14% | 161% | 12.1 | 11 | 1.43 | 74.6% | 16.1% |
HLN NYSE Haleon |
7.98% | 32.4% | 49.3% | 24.4 | 20.2 | 1.79 | 69.1% | 13.6% |
AMGN NASDAQ Amgen |
-7.04% | -11.2% | 27.7% | 25.5 | 13.5 | 0.95 | 0.60% | 41% |
LONN SW Lonza |
11.7% | 13.3% | 33.5% | 67.1 | 35.1 | 1.28 | 2.20% | -12.5% |
BIM PA Biomerieux |
2.2% | 21% | -1.63% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
KMDA NASDAQ Kamada |
13.3% | 27.1% | -5.64% | 27.5 | 25.1 | 1 | 32.5% | 3.93% |
NBIX NASDAQ Neurocrine Biosciences |
27.3% | -15% | 1.88% | 32.3 | 21.6 | 0.27 | 68.0% | 31.9% |
ERF PA Eurofins Scientific SE |
20% | 0.38% | 8.05% | 26.6 | 13.6 | 0.56 | -66.6% | -17.1% |
Performance Comparison: LXRX vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for LXRX
Total Return (including Dividends) | LXRX | XBI | S&P 500 |
---|---|---|---|
1 Month | 36.97% | 2.77% | 5.69% |
3 Months | 0.86% | -14.21% | -6.49% |
12 Months | -62.51% | -14.88% | 9.72% |
5 Years | -67.09% | -26.47% | 107.51% |
Trend Score (consistency of price movement) | LXRX | XBI | S&P 500 |
1 Month | 73.5% | 57% | 89.4% |
3 Months | 2.70% | -82.3% | -72% |
12 Months | -86.5% | -53.1% | 49.3% |
5 Years | -55.4% | -53.9% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #13 | 33.3% | 29.6% |
3 Month | #72 | 17.6% | 7.86% |
12 Month | #126 | -56.0% | -65.8% |
5 Years | #75 | -55.2% | -84.1% |
FAQs
Does LXRX Lexicon outperforms the market?
No,
over the last 12 months LXRX made -62.51%, while its related Sector, the SPDR S&P Biotech (XBI) made -14.88%.
Over the last 3 months LXRX made 0.86%, while XBI made -14.21%.
Over the last 3 months LXRX made 0.86%, while XBI made -14.21%.
Performance Comparison LXRX vs Indeces and Sectors
LXRX vs. Indices LXRX is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | -2.79% | 31.3% | -39.7% | -72.2% |
US NASDAQ 100 | QQQ | -3.06% | 29.6% | -40.1% | -73.3% |
US Dow Jones Industrial 30 | DIA | -2.68% | 34.3% | -38.6% | -68.8% |
German DAX 40 | DAX | -3.24% | 21.9% | -65.2% | -87.3% |
Shanghai Shenzhen CSI 300 | CSI 300 | -3.02% | 34.1% | -38.9% | -68.8% |
Hongkong Hang Seng | HSI | -5.67% | 22.1% | -49.1% | -70.7% |
India NIFTY 50 | INDA | 0.91% | 33.8% | -41.6% | -64.5% |
Brasil Bovespa | EWZ | -5.82% | 25.4% | -48.9% | -56.2% |
LXRX vs. Sectors LXRX is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | -2.16% | 30.5% | -45.8% | -82.9% |
Consumer Discretionary | XLY | -4.21% | 30.3% | -37.5% | -77.3% |
Consumer Staples | XLP | -1.93% | 36.3% | -46.6% | -69.8% |
Energy | XLE | -5.04% | 32.5% | -33.7% | -53.5% |
Financial | XLF | -3.49% | 30.1% | -45.5% | -84.1% |
Health Care | XLV | 1.31% | 40.0% | -34.4% | -56.5% |
Industrial | XLI | -3.72% | 28.7% | -40.6% | -72.9% |
Materials | XLB | -2.95% | 31.9% | -35.6% | -56.4% |
Real Estate | XLRE | -2.0% | 30.1% | -42.0% | -76.1% |
Technology | XLK | -3.63% | 27.3% | -37.4% | -68.6% |
Utilities | XLU | -3.51% | 31.8% | -47.4% | -78.5% |
Aerospace & Defense | XAR | -2.97% | 27.8% | -49.0% | -88.5% |
Biotech | XBI | 4.93% | 34.2% | -18.6% | -47.6% |
Homebuilder | XHB | -2.43% | 31.4% | -26.0% | -53.6% |
Retail | XRT | -2.85% | 30.8% | -33.4% | -56.3% |